AME Bioscience was established in Norway in April 2002.
Our Nordic Division
sells and supports novel life science products throughout the Nordic region.
Latest.................
September 17th 2009
Comprehensive Profiling of miRNAs in Stem Cells Using Microfluidics... (Fluidigm)
August 4th 2009
AME Bioscience is appointed the Nordic distributor for digital ProteomeChip products from Protein Forest.
July 21st 2009
Seegenes Seeplex, effective in identifying Influenza A H1N1
June 30th 2009
Japanese Researchers Use Fluidigm's BioMark Platform for Stem Cell Expression Studies. (Fluidigm)
June 17th 2009
AME Bioscience installs a Fluidigm BioMark System at Olink AB, Uppsala, Sweden.
About AME Bioscience
Worldwide AME Bioscience has developed a large customer base of automated DNA analysis systems, protein analysis and mass spectrometry systems.
We have an investments in a DNA analysis company which has demonstrated excellence in the development of kits for researchers working with infectious disease detection. Other investments include a protein purifcation and labeling company plus partnerships with laboratories using technology we provide on a 'joint venture' basis to enable detection of metabolic disease, genetic disease susceptibility and infectious disease testing.
Our Nordic business focuses mostly on applications of DNA analysis closer to disease identification with innovative and patented PCR technologies as well as new and rapid fluorecent DNA analysis systems. Our Protein products focus on labeling and the ability to very rapidly label proteins, for example antibodies in minutes rather than days to enable rapid development of ELISA assays.
There are many areas of healthcare and disease identification which benefit us, one area which does improve the quality of life for some newborn babies is screening for the detection of inborn errors of metabolism. AME Bioscience has invested with selected laboratories by providing the technology and capability to enable easier access to this testing.
We are always working to enhance the technologies we provide to enable scientists to better discover healthcare benefits and to more specifically and rapidly identify and diagnose disease.